US 10,703,752 B2Granted

Integrin antagonists

AssigneeOxurion NV

InventorsOve Pedersen, Elke Vermassen

Life of this patent

Estimating the term…

Abstract

The present invention relates to novel integrin antagonists of Formula I and their use as a medicament, in particular for inhibiting neovascularization.

Claims5

Dependent claims

A compound according to formula (I), or a pharmaceutically acceptable salt thereof,

wherein
R1 and R2 are independently selected from the group consisting of hydrogen, methyl and ethyl;
and
Alk is C1-4alkylene.

1 more element

Dependencies are inferred from the claim text.

Facts

Application: 16/544,259Filed 19 Aug 2019
Priority: EP 1818961517 Aug 2018
Published: US 2020/0055849 A120 Feb 2020
Granted: 7 Jul 2020
Term ends: Not estimatedThe source records don’t support an estimate.

Classification11 codes

C07D 471/04
In which the condensed system contains two hetero rings: ortho-condensed systems
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61K 9/0048
Galenical forms characterised by the site of application: eye, e.g. artificial tears
A61K 31/506
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim: not condensed and containing further heterocyclic rings

Family

US 2020/0055849 A1Pre-grant publication · published 20 Feb 2020
US 10,703,752 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results